St. Jude Children's Research Hospital
Trial Pipeline
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
NCT06528691
Stakeholders of Rare Diseases Informing Values In Neuroethics
NCT07314736
A Longitudinal Photo-Narrative Exploration of Hope During Phase 1/2 Clinical Trials For Pediatric Cancer
NCT07444216
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
NCT07257419
Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia
NCT07191119
Evaluation Of Cardiovascular Health Outcomes Among Survivors 2
NCT07245420
CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation
NCT07085325
Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas
NCT07222735
Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
NCT06579469
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
NCT07226219
A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
NCT07085338
Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies
NCT06532474
CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions
NCT07048535
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
NCT07052370
Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol
NCT07110519
Culturally Adapted Mobile Treatment of Chronic Pain in Adolescent Survivors of Pediatric Cancer: A Randomized Clinical Trial
NCT07160621
Seminar in Unwavering Empowering Presence Optimized for Rehabilitation Teams
NCT07071116
Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).
NCT05664113
Long Term Follow-Up Study for Individuals With Hemoglobin Disorders After Hematopoietic Cell Transplant or Gene Therapy
NCT06646640
Revealing Information Genuinely & Honestly Across Time - Communication Preferences Visit
NCT06993688
Imaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors
NCT06819475
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
NCT06810583
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
NCT06847269
CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia
NCT06777979
School Readiness Intervention for Preschool Children With Sickle Cell Disease
NCT06367192
Gene Editing For Sickle Cell Disease
NCT06506461
Assessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma
NCT06747910
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
NCT06533748
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
NCT06390319
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
NCT06289673
SCD Stem Cell Mobilization and Apheresis Using Motixafortide
NCT06442761
Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors
NCT06480526
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
NCT06326463
Peripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease
NCT06477289
Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors
NCT06421987
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT06177067
Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
NCT06098430
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
NCT06239272
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
NCT06023641
Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
NCT04881240
Barriers and Facilitators of Parent-Child Communication in Children With Cancer Predisposition
NCT05849155
Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors
NCT05645523
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
NCT05583721
Implementing an Adolescent and Young Adult (AYA) mHealth Vaping Cessation Program Into Oncology Clinics
NCT05967585
Writing Intervention With Adolescents and Young Adults With Cancer
NCT05975333
Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation
NCT05664126
Cognitive Training in the Virtual Reality Setting With Children Undergoing Radiotherapy for Brain Tumors
NCT05947045
Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX)
NCT05810181
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
NCT05835687
Characterizing Sleep Among Long-term Survivors of Childhood Cancer
NCT05480904
Childhood Cancer Survivors' Affective Response to Exercise
NCT05763290
Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products
NCT05713214
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
NCT05535166
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
NCT05468359
Response to Influenza Vaccination in Pediatric Oncology Patients
NCT05384288
The Decision To Enroll In Therapeutic Clinical Trials In A Pediatric Cancer Clinical Network
NCT05454618
Discarded Bone Marrow for Hematology Research
NCT04671212
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
NCT04897321
Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation
NCT04968990
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
NCT04923126
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
NCT04901702
Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors
NCT04764357
Haploidentical HCT for Severe Aplastic Anemia
NCT04558736
Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders
NCT04416178
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
NCT04195347
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
NCT04318678
Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children
NCT04371315
Indocyanine Green (ICG) Guided Tumor Resection
NCT04084067
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
NCT04065776
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
NCT03353584
Familial Investigations of Childhood Cancer Predisposition
NCT03050268
Investigation of the Genetics of Hematologic Diseases
NCT02720679
Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
NCT02775643
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
NCT02530658
Sickle Cell Clinical Research and Intervention Program
NCT02098863
Molecular Analysis Of Solid Tumors
NCT01050296
Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility
NCT01354002
Establishment of a Lifetime of Cohort of Adults Surviving Childhood Cancer
NCT00760656
International Pediatric Adrenocortical Tumor Registry
NCT00700414
Protocol For Collecting Data On Patients With Childhood Cancer
NCT00684580
Pharmacogenetic Determinants Of Treatment Response In Children
NCT00730678
Childhood Cancer Survivor Study
NCT01120353
Complementary Behavioral Interventions To Remediate Cognitive Impairment or Emotional Distress in Cancer Survivors
NCT06989463
Remote Exercise Video Adaptations to Maximize Physical Activity in Childhood Cancer
NCT06411704
Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors
NCT06053268
Cardiovascular Magnetic Resonance Prognosticators in Pediatric Oncology Patients With Sepsis
NCT05930418
Patient- Generated Health Data to Predict Childhood Cancer Survivorship Outcomes
NCT05342155
Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
NCT05656248
Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer
NCT05550948
An Evaluation of Concordance of Smartwatch ECG and One Clinical ECG and Comparison of The Two ECGS in Terms of Predictive Risks
NCT05617391
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
NCT05192889
Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study
NCT05128903
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
NCT05164016
An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer
NCT04733534
An Open-Label Pilot Intervention Trial to Prevent Diabetes in Prediabetic Adult Survivors of Childhood Cancer
NCT04742751
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT04898894
Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)
NCT03597594
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
NCT04551131
Telehealth Based Intervention to Improve Functional Capacity in Survivors of Childhood Cancer With Significantly Limited Exercise Tolerance
NCT04714840
Social Experiences of Adolescents and Young Adults With Cancer
NCT04328350
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 154 |
| Phase 2 | 39 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Therapeutic Areas
What the Pipeline for St. Jude Children's Research Hospital Shows
According to the ClinicalTrials.gov registry, St. Jude Children's Research Hospital is linked to 441 US clinical trials across every stage of research activity. Of those, 346 studies are currently recruiting — about 78% of the sponsor's indexed portfolio — and 41 are already marked complete, representing roughly 9% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for St. Jude Children's Research Hospital reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 193 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for St. Jude Children's Research Hospital is Sickle Cell Disease with 17 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.